Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.

Chuang GY, Acharya P, Schmidt SD, Yang Y, Louder MK, Zhou T, Kwon YD, Pancera M, Bailer RT, Doria-Rose NA, Nussenzweig MC, Mascola JR, Kwong PD, Georgiev IS.

J Virol. 2013 Sep;87(18):10047-58. doi: 10.1128/JVI.00984-13. Epub 2013 Jul 10.

2.

Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

West AP Jr, Scharf L, Horwitz J, Klein F, Nussenzweig MC, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10598-603. doi: 10.1073/pnas.1309215110. Epub 2013 Jun 10.

3.

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.

Evans MC, Phung P, Paquet AC, Parikh A, Petropoulos CJ, Wrin T, Haddad M.

BMC Bioinformatics. 2014 Mar 19;15:77. doi: 10.1186/1471-2105-15-77.

4.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.

Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium..

Virol J. 2013 Dec 2;10:347. doi: 10.1186/1743-422X-10-347.

5.

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC.

J Virol. 2014 Mar;88(5):2489-507. doi: 10.1128/JVI.02853-13. Epub 2013 Dec 18.

7.

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK.

PLoS One. 2013 Dec 2;8(12):e80562. doi: 10.1371/journal.pone.0080562. eCollection 2013.

8.

Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.

Verkerke HP, Williams JA, Guttman M, Simonich CA, Liang Y, Filipavicius M, Hu SL, Overbaugh J, Lee KK.

J Virol. 2016 Sep 29;90(20):9471-82. doi: 10.1128/JVI.01351-16. Print 2016 Oct 15.

9.

Antibody epitope exposure and neutralization of HIV-1.

Pantophlet R.

Curr Pharm Des. 2010;16(33):3729-43. Review.

PMID:
21128886
10.

NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences.

Chuang GY, Liou D, Kwong PD, Georgiev IS.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W64-71. doi: 10.1093/nar/gku318. Epub 2014 Apr 29.

11.

GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.

Wen M, Arora R, Wang H, Liu L, Kimata JT, Zhou P.

Retrovirology. 2010 Oct 6;7:79. doi: 10.1186/1742-4690-7-79.

12.

HIV: Antibodies with a split personality.

Pl├╝ckthun A.

Nature. 2010 Sep 30;467(7315):537-8. doi: 10.1038/467537a. No abstract available.

PMID:
20882002
13.

Challenges for structure-based HIV vaccine design.

Schief WR, Ban YE, Stamatatos L.

Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Review.

PMID:
20048708
14.

Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.

Nie J, Zhao J, Chen Q, Huang W, Wang Y.

Virol Sin. 2014 Oct;29(5):299-307. doi: 10.1007/s12250-014-3485-z. Epub 2014 Sep 28.

PMID:
25273335
15.

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Tong T, Crooks ET, Osawa K, Binley JM.

J Virol. 2012 Apr;86(7):3574-87. doi: 10.1128/JVI.06938-11. Epub 2012 Feb 1.

16.

High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.

Lavine CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, Yang X; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI)..

J Virol. 2012 Feb;86(4):2153-64. doi: 10.1128/JVI.06201-11. Epub 2011 Dec 7.

17.

Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Leaman DP, Lee JH, Ward AB, Zwick MB.

J Virol. 2015 Jul;89(13):6725-45. doi: 10.1128/JVI.03738-14. Epub 2015 Apr 15.

18.

Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Mikell I, Stamatatos L.

PLoS One. 2012;7(11):e49610. doi: 10.1371/journal.pone.0049610. Epub 2012 Nov 13.

19.

Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE Jr.

Mol Immunol. 2016 Feb;70:94-103. doi: 10.1016/j.molimm.2015.12.002. Epub 2015 Dec 31.

20.

Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.

Goo L, Milligan C, Simonich CA, Nduati R, Overbaugh J.

J Virol. 2012 Sep;86(18):9566-82. doi: 10.1128/JVI.00953-12. Epub 2012 Jun 27.

Supplemental Content

Support Center